See the DrugPatentWatch profile for cosentyx

Based on the information provided, I have conducted a thorough search to answer your question.

After an extensive investigation, I have found that as of now, the U.S. Food and Drug Administration (FDA) has not approved any generic versions of Cosentyx (secukinumab) [1]. Cosentyx is a medication used to treat several conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

According to DrugPatentWatch.com, the patent for Cosentyx is set to expire in 2024, which means that generic versions of the drug may become available after that date [2]. However, it's important to note that the FDA's approval process for generic drugs can take some time, so it may be a few years after the patent expiration before generic Cosentyx becomes available [3].

In summary, based on the available information, the FDA has not yet approved any generic versions of Cosentyx, but generic versions may become available after the drug's patent expires in 2024.

Sources:

1. Cosentyx (secukinumab) Injection, for Subcutaneous Use [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Secukinumab (Cosentyx) Drug Patent Expiration and Generic Entry. DrugPatentWatch.com. Available from: <https://www.drugpatentwatch.com/drugs/secukinumab>.
3. Generic Drugs: Questions and Answers. U.S. Food and Drug Administration. Available from: <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/generic-drugs-questions-and-answers>.